23.05 USD
+0.13
0.57%
At close Apr 28, 4:00 PM EDT
Pre-market
23.21
+0.16
0.69%
1 day
0.57%
5 days
3.92%
1 month
-8.57%
3 months
-13.83%
6 months
-20.13%
Year to date
-13.38%
1 year
-10.10%
5 years
-39.20%
10 years
-33.15%
 

About: Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Employees: 81,000

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

43% more first-time investments, than exits

New positions opened: 346 | Existing positions closed: 242

3% more funds holding in top 10

Funds holding in top 10: 40 [Q3] → 41 (+1) [Q4]

2% more funds holding

Funds holding: 2,873 [Q3] → 2,921 (+48) [Q4]

1.21% more ownership

Funds ownership: 64.68% [Q3] → 65.89% (+1.21%) [Q4]

6% less capital invested

Capital invested by funds: $106B [Q3] → $99.6B (-$6.34B) [Q4]

15% less call options, than puts

Call options by funds: $3.27B | Put options by funds: $3.87B

36% less repeat investments, than reductions

Existing positions increased: 919 | Existing positions reduced: 1,446

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$24
4%
upside
Avg. target
$25
10%
upside
High target
$28
21%
upside

4 analyst ratings

positive
0%
neutral
100%
negative
0%
Cantor Fitzgerald
Carter Gould
38% 1-year accuracy
12 / 32 met price target
4%upside
$24
Neutral
Initiated
22 Apr 2025
UBS
Trung Huynh
25% 1-year accuracy
2 / 8 met price target
4%upside
$24
Neutral
Maintained
8 Apr 2025
Goldman Sachs
Asad Haider
100% 1-year accuracy
2 / 2 met price target
8%upside
$25
Neutral
Downgraded
8 Apr 2025
UBS
Colin Bristow
17% 1-year accuracy
2 / 12 met price target
21%upside
$28
Neutral
Maintained
5 Feb 2025

Financial journalist opinion

Based on 123 articles about PFE published over the past 30 days

Neutral
Benzinga
5 hours ago
Pfizer Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Pfizer Inc. PFE will release earnings results for the first quarter, before the opening bell on Tuesday, April 29.
Pfizer Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Positive
Zacks Investment Research
19 hours ago
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?
Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?
Positive
Zacks Investment Research
22 hours ago
4 Top Value Stocks to Invest in as US-Global Trade Talks Unfold
Value investing is essentially about selecting cheap but fundamentally sound stocks. STNE, CSV, ASB & PFE boast low P/CF ratios.
4 Top Value Stocks to Invest in as US-Global Trade Talks Unfold
Positive
The Motley Fool
1 day ago
3 Dividend Stocks to Buy and Hold for the Next Decade
Many income investors would love to have a low-maintenance portfolio that doesn't require constant attention. They'd prefer to buy great stocks and rake in the dividends without any hiccups.
3 Dividend Stocks to Buy and Hold for the Next Decade
Positive
The Motley Fool
1 day ago
My 5 Top Stocks to Buy Right Now in This Highly Volatile Market
Getting dizzy from the stock market's gyrations? Join the club.
My 5 Top Stocks to Buy Right Now in This Highly Volatile Market
Positive
Seeking Alpha
2 days ago
Pfizer: I Am Locking In A 7.5% Dividend Yield Before Earnings
Pfizer's Q1 earnings release is a prime opportunity to secure about a 7.55% dividend yield, with revenue stabilizing post-pandemic and strong cost efficiency. Pfizer's robust product pipeline and consistent R&D investments position it well for future growth, despite past revenue volatility from COVID-19. Valuation metrics indicate Pfizer stock is significantly undervalued, with crucial ratios like Price/Book and Price/Cash Flow much lower than industry averages.
Pfizer: I Am Locking In A 7.5% Dividend Yield Before Earnings
Neutral
Business Wire
2 days ago
Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The trial met its primary endpoint of event-free survival (EFS) by investigator assessment, demonstrating a cli.
Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Neutral
CNBC Television
3 days ago
We're in a pharma stock pickers market, says Kessef's Len Yaffe
Len Yaffe, Kessef Capital Management, joins 'Fast Money' to talk opportunities in the pharma stock space.
We're in a pharma stock pickers market, says Kessef's Len Yaffe
Negative
Reuters
3 days ago
Exclusive: US pharma tariffs would raise US drug costs by $51 bln annually, report finds
A 25% U.S. tariff on pharmaceutical imports would increase U.S. drug costs by nearly $51 billion annually, boosting U.S. prices by as much as 12.9% if passed on, a report commissioned by the industry's U.S. trade group and reviewed by Reuters shows.
Exclusive: US pharma tariffs would raise US drug costs by $51 bln annually, report finds
Positive
24/7 Wall Street
3 days ago
3 High Yield Dividend Stocks Under $25 to Buy and Hold Forever
As income and wealth inequality continue to divide Americans into two distinct classes and levels of wealth, those who are struggling to find investments that can outpace inflation and the growing costs of everyday life are hard-pressed to find options that fit their needs.
3 High Yield Dividend Stocks Under $25 to Buy and Hold Forever
Charts implemented using Lightweight Charts™